Core Insights - Sportsman's Warehouse reported a 2.1% increase in same store sales compared to the previous year, marking the second consecutive quarter of positive comparable sales despite challenging consumer conditions [2][5] - The company's gross margin improved by 80 basis points year-over-year, reaching 32.0% of net sales, driven by better product margins and increased sales in the fishing department [5][6] - The company has raised its fiscal year 2025 sales outlook, expecting net sales to be flat to up 3.5% and reaffirming adjusted EBITDA guidance of $33 million to $45 million [8] Financial Performance - For the thirteen weeks ended August 2, 2025, net sales were $293.9 million, a 1.8% increase from $288.7 million in the same period last year [5][19] - The net loss for the quarter was $(7.1) million, compared to a net loss of $(5.9) million in the prior year, while adjusted net loss improved to $(4.7) million from $(5.3) million [5][11] - Adjusted EBITDA for the quarter was $8.3 million, an increase from $7.4 million in the corresponding prior-year period [5][32] Inventory and Capital Allocation - The company ended the second quarter with inventory of $443.5 million, an increase of $80.1 million year-over-year, as inventory was strategically built ahead of key hunting seasons [11][24] - Total liquidity as of the end of the second quarter was $109.5 million, consisting of $107.7 million available on the revolving credit facility and $1.8 million in cash [11][24] - Capital expenditures for 2025 are expected to be in the range of $20 million to $25 million, primarily for technology investments [8] Strategic Focus - The company is focusing on localizing product assortments and enhancing digital marketing efforts, which have shown positive results in certain markets [2] - The firearms business has outperformed the industry, indicating continued market share gains [2] - The company aims to improve working capital efficiency and reduce debt levels in the latter half of 2025 [8]

Core Insights - CBL International Limited demonstrated resilience in a challenging macroeconomic environment, reporting a consolidated revenue of $265.17 million for the first half of 2025, a 4.4% decrease from the same period in 2024, primarily due to lower marine fuel prices, although sales volume increased [3][9] - The company achieved a significant improvement in net loss, narrowing it by 38.8% to $992,000, driven by disciplined cost management and operational efficiency initiatives [5][9] - CBL's strategic expansion included reaching 65 ports globally, enhancing its service network and enabling it to navigate geopolitical disruptions effectively [7][9] Financial Performance Overview - Consolidated revenue for 1H 2025 was $265.17 million, down from $277.23 million in 1H 2024, attributed to decreased marine fuel prices, partially offset by increased sales volume [3] - Gross profit remained stable at $2.71 million, with a gross profit margin increase from 0.98% in 1H 2024 to 1.02% in 1H 2025, reflecting strategic efforts to maintain profitability [4] - Operating expenses were reduced by 17% to $3.42 million from $4.12 million in 1H 2024, contributing to the improved net loss [5] Strategic Expansion and Operational Excellence - The company expanded its global service network to 65 ports, strategically positioned across various regions, allowing it to capture increased demand amid geopolitical disruptions [7] - Customer diversification improved, with non-container liner sales accounting for 36.9% of revenue, and sales concentration among the top five customers decreased to 60.4% from 66.7% in 1H 2024 [8] - Biofuel sales surged by 154.7% year-on-year, driven by stricter environmental regulations and the successful rollout of the B24 biofuel blend [10][12] Future Outlook - CBL is positioned to capitalize on the growing demand for sustainable marine fuels, with a projected 50.4% CAGR for the green marine fuel market from 2023 to 2030 [12] - The company plans to further scale its biofuel supply chain and explore LNG and methanol, leveraging regulatory support and customer adoption [16] - Management expressed confidence in long-term growth, emphasizing the importance of operational discipline and strategic expansion [13][14]

Core Insights - Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders related to neuronal excitation-inhibition imbalance [1][3] - The company will participate in three upcoming investor conferences, providing opportunities for one-on-one meetings with interested investors [1][4] Company Overview - Praxis utilizes genetic insights from epilepsy to develop therapies for CNS disorders through its proprietary platforms, Cerebrum™ and Solidus™ [3] - The company has a diversified portfolio that includes multiple programs targeting epilepsy and movement disorders, with four clinical-stage product candidates [3] Upcoming Events - Praxis will present at the Baird 2025 Global Healthcare Conference on September 9th from 9:00-9:35am EDT [4] - A fireside chat is scheduled for September 10th at the H.C. Wainwright 27th Annual Global Investment Conference at 8:30am EDT [4] - A virtual corporate presentation will take place on September 18th at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit from 3:00-3:30pm EDT [4]

Another addition to Amneal’s growing complex injectables portfolio reflects leadership in advanced development and manufacturing of complex pharmaceuticals BRIDGEWATER, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of risperidone extended-release injectable suspension 12.5 mg/vial, 25 mg/vial, 37.5 mg/vial and 50 mg/vial, which references Janssen’s Risperdal Consta®. The product is eligib ...

Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastases Decoy20 combination with PD-1 inhibitor, tislelizumab, demonstrates safety profiles consistent with each agent NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces recent updates for the ongoing INDP-D101 clinical tri ...

Daix (France), New York City (New York, United States), September 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in the following upcoming investor events: H.C. Wainwright 27th Annual Global Investment ConferenceDate: Tuesday, September 9, 20 ...

Core Insights - Tevogen Bio Holdings Inc. has announced the potential value and forecast for its pipeline product, TVGN 930, aimed at treating non-solid tumor malignancies associated with Epstein-Barr Virus (EBV) [1][2] Financial Projections - The cumulative 5-year top-line revenue forecast for TVGN 930 is approximately $3.5 billion, reflecting the company's innovative drug development model [2] - The risk-adjusted Net Present Value (rNPV) for TVGN 930 is projected to exceed $250 million in the US alone [7] Market Opportunity - There are currently no approved vaccines for EBV, creating a significant therapeutic gap that TVGN 930 aims to fill [4] - The accessible market in the US for TVGN 930 could potentially cover up to 40,000 patients across five rare disease indications [7] Additional Applications - The treatment of multiple sclerosis through tighter EBV control presents an additional opportunity for the product [3]

A BOGO deal, an AI‑powered content challenge, and a chance to win free fire-grilled chicken for life make this September truly Loco EL POLLO LOCO IS GIVING AWAY UP TO $1 MILLION IN FREE CHICKEN FOR NATIONAL CHICKEN MONTH! Photo: El Pollo Loco COSTA MESA, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- This September, El Pollo Loco is determined to make National Chicken Month more than just a delicious observance – it is planning to own the month with its “Let’s Get Loco” ethos. And they’re kicking it off by g ...

Strong Loan Growth, Prudent Risk Management, and Regulatory Greenlight Position Credilab for Next Phase of ExpansionKUALA LUMPUR, Malaysia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- VCI Global Limited (NASDAQ: VCIG) (“VCI Global” or the “Company”), a cross-sector platform builder integrating deep technology with financial architecture to enable sovereign-ready digital ecosystems, today announced major milestones for its fintech subsidiary, Credilab Sdn Bhd (“Credilab”), as it strengthens its position as an emergin ...

Core Viewpoint - Petrominera S.E. has decided to terminate the joint venture agreement with Interoil Exploration and Production ASA and Selva Maria Oil S.A. due to alleged failures of the Private Companies to meet their obligations [1][2] Company Overview - Interoil Exploration and Production ASA is a Norwegian exploration and production company listed on the Oslo Stock Exchange, focusing on Latin America [3] - The company operates and holds licenses for several production and exploration assets in Colombia and Argentina, with its headquarters located in Oslo [3] Legal Actions - The company is currently assessing appropriate legal actions with its counsel to challenge the legality of Petrominera's termination and to restore its rights [2]